Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 73, No 3 (2022)
Guidelines / Expert consensus
Submitted: 2022-04-26
Accepted: 2022-04-26
Published online: 2022-06-30
View PDF Download PDF file View HTML Supp./Additional Files [2]
Get Citation

Colorectal neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita grubego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]

Teresa Starzyńska1, Magdalena Londzin-Olesik2, Tomasz Bednarczuk3, Marek Bolanowski4, Małgorzata Borowska5, Ewa Chmielik6, Jarosław B. Ćwikła7, Wanda Foltyn2, Iwona Gisterek8, Daria Handkiewicz-Junak9, Alicja Hubalewska-Dydejczyk10, Michał Jarząb11, Roman Junik12, Dariusz Kajdaniuk13, Grzegorz Kamiński14, Agnieszka Kolasińska-Ćwikła15, Aldona Kowalska16, Leszek Królicki17, Jolanta Kunikowska17, Katarzyna Kuśnierz18, Andrzej Lewiński19, Łukasz Liszka20, Bogdan Marek13, Anna Malczewska2, Anna Nasierowska-Guttmejer21, Ewa Nowakowska-Duława22, Marianne E. Pavel23, Joanna Pilch-Kowalczyk24, Jarosław Reguła25, Violetta Rosiek2, Marek Ruchała26, Grażyna Rydzewska27, Lucyna Siemińska13, Anna Sowa-Staszczak10, Zoran Stojčev28, Janusz Strzelczyk2, Michał Studniarek29, Anhelli Syrenicz30, Marek Szczepkowski31, Ewa Wachuła32, Wojciech Zajęcki5, Anna Zemczak2, Wojciech Zgliczyński33, Krzysztof Zieniewicz34, Beata Kos-Kudła2
DOI: 10.5603/EP.a2022.0053
·
Pubmed: 36059175
·
Endokrynol Pol 2022;73(3):584-611.
Affiliations
  1. Department of Gastroenterology, Medical Pomeranian University in Szczecin, Szczecin, Poland
  2. Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
  3. Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
  4. Chair and Department of Endocrinology, Diabetes, and Isotope Therapy, Medical University of Wroclaw, Wroclaw, Poland
  5. Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland
  6. Tumor Pathology Department, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  7. Department of Cardiology and Internal Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland
  8. Chair of Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland
  9. Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Brench, Gliwice, Poland
  10. Chair and Department of Endocrinology, Jagiellonian University Medical College, Cracow, Poland
  11. Breast Unit, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  12. Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
  13. Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
  14. Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland
  15. Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Warsaw, Poland
  16. Department of Endocrinology, Holycross Cancer Centre, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  17. Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland
  18. Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland
  19. Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
  20. Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland
  21. Faculty of Medicine, Lazarski University in Warsaw, Warsaw, Poland
  22. Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland
  23. Department of Medicine 1, Endocrinology and Diabetology, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany
  24. Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland;
  25. Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Warsaw, Poland
  26. Department of Endocrinology, Metabolism and Internal Diseases, Medical University in Poznan, Poznan, Poland
  27. Department of Internal Medicine and Gastroenterology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
  28. Department of Oncology and Breast Diseases, Centre of Postgraduate Medical Education, Warsaw, Poland
  29. Department of Radiology, Medical University of Gdansk, Gdansk, Poland
  30. Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, Poland
  31. Clinical Department of Colorectal, General and Oncological Surgery, Centre of Postgraduate Medical Education, Warsaw, Poland
  32. Department of Clinical Oncology, Gdynia Oncology Centre of the Polish Red Cross Maritime Hospital, Gdynia, Poland
  33. Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland
  34. Chair and Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland

open access

Vol 73, No 3 (2022)
Guidelines
Submitted: 2022-04-26
Accepted: 2022-04-26
Published online: 2022-06-30

Abstract

Colorectal neuroendocrine neoplasm (CRNEN), especially rectal tumours, are diagnosed with increased frequency due to the widespread use of colonoscopy, including screening examinations. It is important to constantly update and promote the principles of optimal diagnostics and treatment of these neoplasms. Based on the latest literature and arrangements made at the working meeting of the Polish Network of Neuroendocrine Tumours (June 2021), this paper includes updated and supplemented data and guidelines for the management of CRNEN originally published in Endokrynologia Polska 2017; 68: 250–260.

Abstract

Colorectal neuroendocrine neoplasm (CRNEN), especially rectal tumours, are diagnosed with increased frequency due to the widespread use of colonoscopy, including screening examinations. It is important to constantly update and promote the principles of optimal diagnostics and treatment of these neoplasms. Based on the latest literature and arrangements made at the working meeting of the Polish Network of Neuroendocrine Tumours (June 2021), this paper includes updated and supplemented data and guidelines for the management of CRNEN originally published in Endokrynologia Polska 2017; 68: 250–260.

Full Text:

View PDF Download PDF file View HTML Supp./Additional Files [2]
Get Citation

Keywords

colorectal neuroendocrine neoplasms; diagnosis; treatment; monitoring

Supp./Additional Files (2)
Supplementary File [Materiały dodatkowe] — Tab. S. 1, S2
Download
80KB
Conflict of interests [Konflikt interesów]
Download
319KB
About this article
Title

Colorectal neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita grubego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]

Journal

Endokrynologia Polska

Issue

Vol 73, No 3 (2022)

Article type

Guidelines / Expert consensus

Pages

584-611

Published online

2022-06-30

Page views

4917

Article views/downloads

1160

DOI

10.5603/EP.a2022.0053

Pubmed

36059175

Bibliographic record

Endokrynol Pol 2022;73(3):584-611.

Keywords

colorectal neuroendocrine neoplasms
diagnosis
treatment
monitoring

Authors

Teresa Starzyńska
Magdalena Londzin-Olesik
Tomasz Bednarczuk
Marek Bolanowski
Małgorzata Borowska
Ewa Chmielik
Jarosław B. Ćwikła
Wanda Foltyn
Iwona Gisterek
Daria Handkiewicz-Junak
Alicja Hubalewska-Dydejczyk
Michał Jarząb
Roman Junik
Dariusz Kajdaniuk
Grzegorz Kamiński
Agnieszka Kolasińska-Ćwikła
Aldona Kowalska
Leszek Królicki
Jolanta Kunikowska
Katarzyna Kuśnierz
Andrzej Lewiński
Łukasz Liszka
Bogdan Marek
Anna Malczewska
Anna Nasierowska-Guttmejer
Ewa Nowakowska-Duława
Marianne E. Pavel
Joanna Pilch-Kowalczyk
Jarosław Reguła
Violetta Rosiek
Marek Ruchała
Grażyna Rydzewska
Lucyna Siemińska
Anna Sowa-Staszczak
Zoran Stojčev
Janusz Strzelczyk
Michał Studniarek
Anhelli Syrenicz
Marek Szczepkowski
Ewa Wachuła
Wojciech Zajęcki
Anna Zemczak
Wojciech Zgliczyński
Krzysztof Zieniewicz
Beata Kos-Kudła

References (109)
  1. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006; 355(18): 1863–1872.
    CrossRefPubMed
  2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4): 934–959.
    CrossRefPubMed
  3. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128(6): 1717–1751.
    CrossRefPubMed
  4. Tichansky DS, Cagir B, Borrazzo E, et al. Risk of second cancers in patients with colorectal carcinoids. Dis Colon Rectum. 2002; 45(1): 91–97.
    CrossRefPubMed
  5. Bogacka B, Marlicz W, Białek A, et al. Trends in colorectal neuroendocrine tumors: A 10 years review. Gut. 2009; 58: A296.
  6. Kamiński MF, Polkowski M, Reguła J, et al. Prevalence and endoscopic features of rectal neuro-endocrine tumours among 50 148 participants of the Polish Colorectal-Cancer Screening Pro-gramme. Gut. 2007; 56: A310.
  7. Caplin M, Sundin A, Nillson O, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012; 95(2): 88–97.
    CrossRefPubMed
  8. Starzyńska T, Londzin-Olesik M, Bałdys-Waligórska A, et al. Colorectal neuroendocrine neoplasms — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2017; 68(2): 250–260.
    CrossRefPubMed
  9. Ramage JK, De Herder WW, Delle Fave G, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016; 103(2): 139–143.
    CrossRefPubMed
  10. Zhang Yu, Chen HY, Zhou XL, et al. Diagnostic efficacy of the Japan Narrow-band-imaging Expert Team and Pit pattern classifications for colorectal lesions: A meta-analysis. World J Gastroenterol. 2020; 26(40): 6279–6294.
    CrossRefPubMed
  11. Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020; 29(2): 185–208.
    CrossRefPubMed
  12. Federspiel B, Burke A, Sobin L, et al. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer. 1990; 65(1): 135–140, doi: 10.1002/1097-0142(19900101)65:1<135::aid-cncr2820650127>3.0.co;2-a.
    PubMed
  13. Xu Z, Wang Li, Dai S, et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open. 2021; 4(9): e2124750.
    CrossRefPubMed
  14. Rosenberg J, Welch J. Carcinoid tumors of the colon. Am J Surg. 1985; 149(6): 775–779.
    CrossRefPubMed
  15. Anthony LB, Strosberg JR, Klimstra DS, et al. North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas. 2010; 39(6): 767–774.
    CrossRefPubMed
  16. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer. 2005; 103(8): 1587–1595.
    CrossRefPubMed
  17. Yoon SN, Yu CS, Shin UiS, et al. Clinicopathological characteristics of rectal carcinoids. Int J Colorectal Dis. 2010; 25(9): 1087–1092.
    CrossRefPubMed
  18. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–3072.
    CrossRefPubMed
  19. Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 2020; 12(8): 791–807.
    CrossRefPubMed
  20. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018; 68(6): 471–487.
    CrossRefPubMed
  21. Modlin I, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 2000; 79(4): 813–829, doi: 10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2.
    PubMed
  22. Jetmore AB, Ray JE, Gathright JB, et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum. 1992; 35(8): 717–725.
    CrossRefPubMed
  23. Gleeson FC, Levy MJ, Dozois EJ, et al. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointest Endosc. 2014; 80(1): 144–151.
    CrossRefPubMed
  24. Fine C, Roquin G, Terrebonne E, et al. Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE). United European Gastroenterol J. 2019; 7(8): 1102–1112.
    CrossRefPubMed
  25. Mełeń-Mucha G, Mucha S, Komorowski J. Early detection of gastric GIST tumor in a patient with rectal neuroendocrine cancer — a case report. 8th Annual ENETS Conference for the Diag-nosis and Treatment of Neuroendocrine Tumor Disease, 9–11 March 2011, Lisbon, Portugal. Neuroendocrinology. 2011; 94(Suppl 1): 36–37.
  26. Kölby L, Bernhardt P, Swärd C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept. 2004; 120(1-3): 269–273.
    CrossRefPubMed
  27. Kos-Kudła B, Foltyn W, Malczewska A, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022; 73(3): 387–423.
    CrossRef
  28. Klöppel G, Couvelard A, Hruban RH. et al. Tumours of the endocrine pancreas. In: Lloyd RV, Hruban RH, Osamura RY, Klöppel G, Rosai J, eds WHO. ed. Classification of the Tumours of Endocrine Organs. 4th ed. International Agency for Research on Cancer, Lyon 2017: 175–207.
  29. Heetfeld M, Chougnet CN, Olsen IH, et al. other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015; 22(4): 657–664.
    CrossRefPubMed
  30. Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev. 2016; 50: 61–67.
    CrossRefPubMed
  31. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018; 31(12): 1770–1786.
    CrossRefPubMed
  32. WHO Classification of Tumours Editorial Boards. Digestive system tumours. In: WHO classification of tumours series. 5th ed. International Agency for Research on Cancer, Lyon 2019.
  33. Brierley J, Gospodarowicz MK, Wittekind Ch. TNM classification of malignat tumours. 8th ed. Wiley Blackwell, Oxford 2017: Wiley.
  34. Woltering EA, Bergsland EK, Beyer DT. et al. Neuroendocrine tumors of the jejunum and ileum. American Joint Committee on Cancer 2017. In: Amin MB. ed. ed. AJCC Cancer Staging Manual. 8th ed. Springer, New York 2017: 375–387.
  35. Wittekind C, Compton C, Quirke P, et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer. 2009; 115(15): 3483–3488.
    CrossRefPubMed
  36. Lin CK, Chung CS, Huang WC. Rectal carcinoid tumour observed by magnifying colonoscopy with narrow band imaging. Dig Liver Dis. 2014; 46(7): e7.
    CrossRefPubMed
  37. Mori Y, Kudo SE, Misawa M, et al. Simultaneous detection and characterization of diminutive polyps with the use of artificial intelligence during colonoscopy. VideoGIE. 2019; 4(1): 7–10.
    CrossRefPubMed
  38. Mori Y, Kudo SE, East JE, et al. Cost savings in colonoscopy with artificial intelligence-aided polyp diagnosis: an add-on analysis of a clinical trial (with video). Gastrointest Endosc. 2020; 92(4): 905–911.e1.
    CrossRefPubMed
  39. Hosoe N, Limpias Kamiya KJL, Hayashi Y, et al. Current status of colon capsule endoscopy. Dig Endosc. 2021; 33(4): 529–537.
    CrossRefPubMed
  40. Hawes RH, Fockens P, Varadarajulu S. Endosonography. Saunders Elsevier 2015.
  41. Chen L, Guo Yu, Zhang Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors. Endoscopy. 2021; 53(7): 702–709.
    CrossRefPubMed
  42. Fu KI, Mashimo Y, Matsuda T, et al. Is endoscopic ultrasonography necessary for depth evaluation of rectal carcinoid tumors CrossRefPubMed
  • Gu Q, Lin YM, Cen Li, et al. Endoscopic ultrasonography is useful in the diagnosis and treatment of rectal neuroendocrine neoplasms: a case series. J Zhejiang Univ Sci B. 2019; 20(10): 861–864.
    CrossRefPubMed
  • Hamada Y, Tanaka K, Hattori A, et al. Clinical utility of endoscopic submucosal dissection using the pocket-creation method with a HookKnife and preoperative evaluation by endoscopic ultrasonography for the treatment of rectal neuroendocrine tumors. Surg Endosc. 2022; 36(1): 375–384.
    CrossRefPubMed
  • Stier MW, Chapman CG, Shamah S, et al. Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor. Endosc Int Open. 2021; 9(1): E4–E8.
    CrossRefPubMed
  • Sundin A, Arnold R, Baudin E, et al. Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017; 105(3): 212–244.
    CrossRefPubMed
  • Ronot M, Cuccioli F, Dioguardi Burgio M, et al. Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. Eur J Radiol. 2017; 89: 156–162.
    CrossRefPubMed
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–247.
    CrossRefPubMed
  • Schraml C, Schwenzer NF, Sperling O, et al. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013; 13: 63–72.
    CrossRefPubMed
  • Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013; 24(1): 152–160.
    CrossRefPubMed
  • Garcia-Carbonero R, Sorbye H, Baudin E, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016; 103(2): 186–194.
    CrossRefPubMed
  • Kunikowska J, Lewington V, Krolicki L. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management. Clin Nucl Med. 2017; 42(12): 905–911.
    CrossRefPubMed
  • Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021; 146: 56–73.
    CrossRefPubMed
  • Hicks RJ, Kwekkeboom DJ, Krenning E, et al. Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017; 105(3): 295–309.
    CrossRefPubMed
  • Binderup T, Knigge U, Loft A, et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010; 16(3): 978–985.
    CrossRefPubMed
  • Bahri H, Laurence L, Edeline J, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014; 55(11): 1786–1790.
    CrossRefPubMed
  • Dąbkowski K, Szczepkowski M, Kos-Kudła B, et al. Endoscopic management of rectal neuroendocrine tumours. How to avoid a mistake and what to do when one is made? Endokrynol Pol. 2020; 71(4): 343–349.
    CrossRefPubMed
  • Chen WJ, Wu N, Zhou JL, et al. Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors. World J Gastroenterol. 2015; 21(30): 9142–9149.
    CrossRefPubMed
  • Shao Q, Lin G, Qiu H. [Transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017; 20(9): 1009–1014.
    PubMed
  • Kumar AS, Sidani SM, Kolli K, et al. Transanal endoscopic microsurgery for rectal carcinoids: the largest reported United States experience. Colorectal Dis. 2012; 14(5): 562–566.
    CrossRefPubMed
  • Meier B, Albrecht H, Wiedbrauck T, et al. Full-thickness resection of neuroendocrine tumors in the rectum. Endoscopy. 2020; 52(1): 68–72.
    CrossRefPubMed
  • Szczepkowski M, Banasiewicz T, Krokowicz P, et al. et al.. Polski konsensus w sprawie stomii protekcyjnej. Przeg Chir. 2014; 86: 717–741.
  • Jernman J, Hagström J, Mäenpää H, et al. Expression of Stem Cell-associated Marker HES77 in Rectal Neuroendocrine Tumors. Anticancer Res. 2015; 35(7): 3767–3772.
    PubMed
  • Al-Jiffry BO, Al-Malki O. Neuroendocrine small cell rectal cancer metastasizing to the liver: a unique treatment strategy, case report, and review of the literature. World J Surg Oncol. 2013; 11: 153.
    CrossRefPubMed
  • Ringe B, Lorf T, Döpkens K, et al. Treatment of hepatic metastases from gastroenteropancreatic neuroendocrine tumors: role of liver transplantation. World J Surg. 2001; 25(6): 697–699.
    CrossRefPubMed
  • Pavel M, O'Toole D, Costa F, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016; 103(2): 172–185.
    CrossRefPubMed
  • Al Natour RH, Saund MS, Sanchez VM, et al. Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. J Gastrointest Surg. 2012; 16(3): 595–602.
    CrossRefPubMed
  • Zhao B, Hollandsworth HM, Lopez NE, et al. Outcomes for a Large Cohort of Patients with Rectal Neuroendocrine Tumors: an Analysis of the National Cancer Database. J Gastrointest Surg. 2021; 25(2): 484–491.
    CrossRefPubMed
  • Ngamruengphong S, Kamal A, Akshintala V, et al. Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors. Gastrointest Endosc. 2019; 89(3): 602–606.
    CrossRefPubMed
  • Gu MG, Lee SiH. [Endoscopic Treatment Outcome of Rectal Neuroendocrine Tumors Removed by Ligation-assisted Endoscopic Submucosal Resection]. Korean J Gastroenterol. 2018; 72(3): 128–134.
    CrossRefPubMed
  • Lim HK, Lee SJ, Baek DH, et al. Resectability of Rectal Neuroendocrine Tumors Using Endoscopic Mucosal Resection with a Ligation Band Device and Endoscopic Submucosal Dissection. Gastroenterol Res Pract. 2019; 2019: 8425157.
    CrossRefPubMed
  • Wang XY, Chai NL, Linghu EQ, et al. The outcomes of modified endoscopic mucosal resection and endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors and the value of endoscopic morphology classification in endoscopic resection. BMC Gastroenterol. 2020; 20(1): 200.
    CrossRefPubMed
  • Lee J, Park YE, Choi JH, et al. Comparison between cap-assisted and ligation-assisted endoscopic mucosal resection for rectal neuroendocrine tumors. Ann Gastroenterol. 2020; 33(4): 385–390.
    CrossRefPubMed
  • So H, Yoo SuH, Han S, et al. Efficacy of Precut Endoscopic Mucosal Resection for Treatment of Rectal Neuroendocrine Tumors. Clin Endosc. 2017; 50(6): 585–591.
    CrossRefPubMed
  • Wang XY, Chai NL, Linghu EQ, et al. Efficacy and safety of hybrid endoscopic submucosal dissection compared with endoscopic submucosal dissection for rectal neuroendocrine tumors and risk factors associated with incomplete endoscopic resection. Ann Transl Med. 2020; 8(6): 368.
    CrossRefPubMed
  • Suzuki S, Ishii N, Uemura M, et al. Endoscopic submucosal dissection (ESD) for gastrointestinal carcinoid tumors. Surg Endosc. 2012; 26(3): 759–763.
    CrossRefPubMed
  • Lee EJ, Lee JB, Lee SH, et al. Endoscopic submucosal dissection for colorectal tumors — 1,000 colorectal ESD cases: one specialized institute's experiences. Surg Endosc. 2013; 27(1): 31–39.
    CrossRefPubMed
  • Kim JiH, Baek IlH, Kim KOh, et al. Usefulness and feasibility of endoscopic submucosal dissection for colorectal tumor: a nationwide multicenter retrospective study in Korea. J Gastrointest Oncol. 2016; 7(6): 924–930.
    CrossRefPubMed
  • Brand M, Reimer S, Reibetanz J, et al. Endoscopic full thickness resection vs. transanal endoscopic microsurgery for local treatment of rectal neuroendocrine tumors - a retrospective analysis. Int J Colorectal Dis. 2021; 36(5): 971–976.
    CrossRefPubMed
  • Aepli P, Criblez D, Baumeler S, et al. Endoscopic full thickness resection (EFTR) of colorectal neoplasms with the Full Thickness Resection Device (FTRD): Clinical experience from two tertiary referral centers in Switzerland. United European Gastroenterol J. 2018; 6(3): 463–470.
    CrossRefPubMed
  • Kim J, Kim JH, Lee JY, et al. Clinical outcomes of endoscopic mucosal resection for rectal neuroendocrine tumor. BMC Gastroenterol. 2018; 18(1): 77.
    CrossRefPubMed
  • Dąbkowski K, Rusiniak-Rossińska N, Michalska K, et al. Endoscopic treatment of rectal neuroendocrine tumors in a 13-year retrospective single-center study: are we following the guidelines? Pol Arch Intern Med. 2021; 131(3): 241–248.
    CrossRefPubMed
  • Pagano N, Ricci C, Brighi N, et al. Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience. Endocrine. 2019; 65(1): 207–212.
    CrossRefPubMed
  • Frei R. ENOSWISS 2021.
  • Caplin ME, Pavel M, Ćwikła JB, et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3): 224–233.
    CrossRefPubMed
  • Berardi R, Rinaldi S, Torniai M, et al. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. Crit Rev Oncol Hematol. 2016; 98: 264–274.
    CrossRefPubMed
  • Pavel M, Hainsworth J, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378(9808): 2005–2012.
    CrossRefPubMed
  • Yao J, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387(10022): 968–977.
    CrossRefPubMed
  • Pavel M, Öberg K, Falconi M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7): 844–860.
    CrossRefPubMed
  • Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007; 59(5): 637–642.
    CrossRefPubMed
  • Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012; 19(6): 751–757.
    CrossRefPubMed
  • Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011; 117(20): 4617–4622.
    CrossRefPubMed
  • Olsen IH, Sørensen JB, Federspiel B, et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal. 2012; 2012: 170496.
    CrossRefPubMed
  • Koumarianou A, Kaltsas G, Kulke MH, et al. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology. 2015; 101(4): 274–288.
    CrossRefPubMed
  • Mitry E, Walter T, Baudin E, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. Eur J Cancer. 2014; 50(18): 3107–3115.
    CrossRefPubMed
  • Sahu A, Jefford M, Lai-Kwon J, et al. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. J Oncol. 2019; 2019: 9032753.
    CrossRefPubMed
  • Luong TuV, Nisa Z, Watkins J, et al. Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas? Endocrinol Diabetes Metab Case Rep. 2020 [Epub ahead of print]; 2020.
    CrossRefPubMed
  • Fraune C, Simon R, Hube-Magg C, et al. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocr Pathol. 2020; 31(2): 182–189.
    CrossRefPubMed
  • Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging. 2019; 46(3): 718–727.
    CrossRefPubMed
  • Kunikowska J, Pawlak D, Bąk MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Y/Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017; 31(5): 347–356.
    CrossRefPubMed
  • Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using Y/Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020; 47(4): 922–933.
    CrossRefPubMed
  • Zemczak A, Kołodziej M, Gut P, et al. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT? Endokrynol Pol. 2020; 71(3): 240–248.
    CrossRefPubMed
  • Hörsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016; 58: 41–51.
    CrossRefPubMed
  • Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018; 9(24): 16932–16950.
    CrossRefPubMed
  • Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016; 103(2): 186–194.
    CrossRefPubMed
  • Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10): 2655–2664.
    CrossRefPubMed
  • Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020; 49(7): 863–881.
    CrossRefPubMed
  • European Society for Medical Oncology. Standard Operating Procedures (SOPs) for Authors and templates for ESMO Clinical Practice Guidelines (CPGs) and ESMO-MCBS Scores 2021. https://www.esmo.org/content/download/77789/1426712/file/ESMO-Clinical-Practice-Guidelines-Standard-Operating-Procedures.pdf.
  • The National Comprehensive Cancer Network. About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2020. https://www.nccn.org/professionals/default.aspx.

    • Regulations

    Important: This website uses cookies. More >>

    The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

    Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

    tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl